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The process of immunologically mediated phagocytosis can be divided into three
steps: (a) attachment of a ligand-coated particle to specific receptors on the phagocytic
cell's plasma membrane; (b) generation and transmission of a phagocytic signal by
receptor-ligand engagement; and (c) the ingestion process per se (1) . Depending upon
the receptor engaged and the physiologic state of the phagocytic cell, the process may
or may not proceed to completion. For example, engagement of macrophage Fc
receptors by particle-bound IgG virtually always leads to particle ingestion (2-5) . In
contrast, engagement of macrophage complement receptors by particle-bound C3b,
which always mediates efficient particle binding (2-8), promotes particle ingestion
only by macrophages that have been physiologically altered (5-8) .
Recent studies by Michl et al. (9, 10) suggest that for a receptor to promote particle
ingestion, it must be able to move within the plane of the cell's plasma membrane.
The Fc receptors of both resident and thioglycollate-elicited mouse peritoneal mac-
rophages mediate both attachment and ingestion of IgG-coated particles (2, 3, 6) .
The C3b receptor of resident macrophages mediates only attachment of C3b-coated
particles (2, 3), whereas the C3b receptor of thioglycollate-elicited macrophages
promotes ingestion as well (6) . Michl et al . (9) found that when macrophages were
plated on coverslips coated with antigen-antibody complexes, the Fc receptor activity
of both resident and thioglycollate-elicited macrophages disappeared from the non-
adherent surface of the cells. When macrophages were plated on coverslips coated
with antigen-antibody-complement complexes, the C3b receptor activity of thiogly-
collate-elicited macrophages also disappeared, but that of resident macrophages did
not. Subsequent studies (10) provided indirect evidence that the disappearance of
receptor activity from the nonadherent macrophage surface was the result of receptor
migration within the plane of the macrophage plasma membrane to the immobilized
ligand. The correlation of the ability of these receptors to redistribute on the
macrophage surface with their ability to promote phagocytosis suggested that receptor
mobility may be a prerequisite for particle ingestion.
We have previously reported that treatment with a unique lymphokine enables
resident mouse peritoneal macrophages to phagocytize via their complement receptors
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(7, 8) and have presented evidence that the lymphokine acts by enabling complement
receptor engagement by C3b ligands to generate a phagocytic signal, thereby linking
the cell surface binding event with the intracellular phagocytic machinery (8) . In the
present experiments, we used techniques similar to those of Michl et al. (9, 10) to
study the topography of C3b receptors of resident mouse peritoneal macrophages
treated with the lymphokine. Our results indicate that lymphokine treatment enables
the macrophages' C3b receptors to migrate within the plane of the cells' plasma
membrane and that manipulations of macrophages that abrogate one response to the
lymphokine, complement receptor mobility, also abrogate the other response, com-
plement receptor-mediated phagocytosis. These findings strongly suggest that lateral
mobility of a ligand-bound receptor within the macrophage plasma membrane is an
essential component of the phagocytic signal. Moreover, our results indicate that the
difference in complement receptor function among various populations of macro-
phages is not due to the expression of different types of complement receptors by the
different macrophage populations but rather to a difference in the relationship of the
C3b receptor with other plasma membrane or intracellular components.
Materials and Methods
Reagents and Media.
￿
Glycine, bovine serum albumin (BSA),' colchicine, vinblastine, and
cyclohexamide were obtained from Sigma Chemical Co., St. Louis, Mo. ; chromerge, glutaral-
dehyde, 50% aqueous solution, and concentrated sulfuric acid were purchased from Fisher
Scientific Co., Atlanta, Ga.; medium 199 was purchased from Microbiological Associates,
Walkersville, Md.; fetal bovine serum (FBS) and penicillin-streptomycin were obtained from
Grand Island Biological Company, Grand Island, N. Y.; poly-L-lysine (PLL) was purchased
from Miles Laboratories, Elkhart, Ind.; and Brewer thioglycollate medium was obtained from
Difco Laboratories, Detroit, Mich. FBS was heat inactivated (56°C for 30 min) before use.
Lyophilized rabbit anti-BSA IgG was obtained from N. L. Cappel Laboratories, Inc.,
Cochranville, Pa. It was reconstituted at 6 mg/ml of antibody protein according to the
manufacturer's directions in phosphate-buffered saline (PBS), pH 7.4, and was further diluted
in medium for use in experiments as indicated. Sheep erythrocytes (E) in Alsever's solution,
obtained from Scott Laboratories, Fiskeville, R. I., were washed three times in PBS without
Mg` and Ca" (PD) and resuspended in medium. A 4.05% aqueous solution of Brewer
thioglycollate medium was prepared according to the manufacturer's directions. Lumicolchicine
was prepared in PBS as previously described (11). Taxol was a generous gift from Dr. J. Smith,
University of Alabama in Birmingham.
Immunologically Coated Sheep E.
￿
Rabbit anti-sheep E IgM and rabbit anti-sheep E IgG were
obtained from Cordis Laboratories, Miami, Fla. Sheep E coated with anti-E IgG [E(IgG)] or
with anti-E IgM and the first four complement components [E(IgM)C] were prepared as
previously described (3) .
Animals.
￿
Peritoneal macrophages and mouse serum used to prepare immobilized immune
complexes were obtained from 20-30 g female, CD-1 Swiss mice (Charles River Breeding
Laboratories, Inc., Wilmington, Mass.) . C5-deficient mouse serum was obtained from female,
C5-deficient AKR mice (The Jackson Laboratory, Bar Harbor, Maine). Both AKR and CD-1
mouse serum were adsorbed twice at 4° C for 15 min with 20% sheep E before being frozen in
small aliquots at -70°C. Serum was thawed on ice just before use as a complement source.
Macrophages.
￿
Resident mouse peritoneal macrophages were obtained by peritoneal lavage
and cultured (2 X 105/well) in medium in 24-well tissue culture clusters (Costar Bellco Glass,
Inc., Vineland, N. J.) . Macrophages elicited with thioglycollate medium were harvested 4 d
' Abbreviations used in this paper: BSA, bovine serum albumin; BSA-anti-BSA-C, complement-containing
BSA-anti-BSA complexes; C3b INA, C3b inactivator; E, erythrocytes; E(IgG), E coated with anti-E IgG;
E(IgM)C, E coated with anti-E IgM and the first four complement components; FBS, fetal bovine serum;
PBS, phosphate-buffered saline; PD, PBS without Ca" or Mg` ions; PLL, poly-L-lysine.FRANK M. GRIFFIN, JR . AND PEGGY J . MULLINAX
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after intraperitoneal injection of 1 ml/mouse of thioglycollate medium and cultured (1 .25 X
106/well) in the same manner as resident peritoneal macrophages .
Preparation of Coverslips.
￿
Immobilized immune complexes were fixed onto 13-mm glass
coverslips as previously described (9) . Coverslips were cleaned overnight at room temperature
with 1% chromerge in concentrated sulfuric acid, washed for 2-4 h in running water, rinsed
with distilled water, dried, and stored at room temperature . They were then incubated in PD
containing 0.1 mg/ml ofPLL for 30 min at room temperature, washed in PD, incubated for 15
min at room temperature in 2.5% glutaraldehyde in PD, washed with distilled water and then
with PD, and reacted for 30 min at room temperature with 3 mg/ml of BSA in PD . The
reaction with BSA was stopped by overnight incubation at room temperature in 0.2 M glycine
in PD, after which coverslips were either used immediately or stored at 4°C . Before further
treatment, coverslips were washed twice with PD and placed into 24-well cluster plates.
To prepare immobilized immune complexes, 100 jug of anti-BSA IgG in 0.5 ml of medium
was added to each well, coverslips were incubated for 30 min at room temperature, washed
with PD, and used the same day. To prepare complement-containing complexes (BSA-anti-
BSA-C), neat fresh mouse serum was added directly to the wells (75 Al/well) containing
cover-slips coated with BSA-anti-BSA complexes . Coverslips were incubated for 10 min at 37°C,
washed with PD, and used the same day.
Preparation ofLymphokine.
￿
Culture supernates containing the lymphokine that enables resi-
dent mouse peritoneal macrophages to ingest C3b-coated particles were prepared and used as
previously described (7, 8) .
Inhibition of Macrophage Protein Synthesis .
￿
Macrophage protein synthesis was blocked by
incubating the cells with 5 Ag/ml of cyclohexamide for 1 h at 37°C, treatment that we have
previously shown inhibits protein synthesis by >85% (8) .
Assessment of Macrophage Fc and Cab Receptor Function.
￿
After a 1-h incubation at 37 °C to
permit spreading of macrophages on coverslips, monolayers were washed twice with PBS and
overlaid with 1 ml of either medium or lymphokine. After a 15-min incubation at 37°C, some
cultures were washed and covered with 1 ml of fresh medium ; others were not washed . 0.1 ml
of 0.5% E(IgG) or E(IgM)C was added to the wells and cultures were incubated for 1 h at
37°C . The cultures were then washed twice with PBS and fixed with 2.5% glutaraldehyde in
0 .1 M cacodylate buffer, and E attachment and ingestion were scored by phase-contrast
microscopy .
Miscellaneous.
￿
Viability of macrophages plated on coverslips coated withimmune complexes
was assessed by their ability to exclude 0.4% trypan blue dye after 10 min at room temperature .
Protein concentrations were determined by the method of Lowry et al . (12), using BSA as a
standard .
Presentation of Results.
￿
Each result reported is the average of at least three separate determi-
nations, each performed in duplicate . The attachment index and the phagocytic index are the
number of E attached or ingested by 100 macrophages and were obtained by multiplying the
percent of macrophages that had attached or ingested any E by the average number of E
attached or ingested per macrophage . Each result is presented as mean f SEM .
Results
Effects of Immobilized Immune Complexes on the Topography of Macrophage C3b
Receptors. Resident and thioglycollate-elicited macrophages were plated on cover-
slips, some of which were coated with immune complexes . Some resident macrophages
were treated with lymphokine, and each population was incubated with E(IgM)C
(Table I) . All macrophages plated on coverslips that had received no treatment avidly
bound E(IgM)C ; thioglycollate-elicited and lymphokine-treated macrophages also
ingested E(IgM)C, whereas resident macrophages did not (Table I, line 1) . The
abilities of macrophages to bind and to ingest E coated with C3b were not affected by
plating the cells on coverslips coated with eitherPLL and BSA orPLL and BSA-anti-
BSA (Table I, lines 2 and 3) . The complement receptor activity of resident macro-
phages plated on BSA-anti-BSA-C was not reduced (Table 1, line 4, column 2) .294
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TABLE I
Interaction ofMouse Peritoneal Macrophages with E(IgM)C
* PI, phagocytic index ; AI, attachment index .
Macrophages*
However, the abilities of both thioglycollate-elicited and lymphokine-treated macro-
phages to bind and to ingest E(IgM)C was abolished by plating them on complement-
containing complexes (Table I, line 4, columns 3-6) . In parallel experiments, we
confirmed that resident, thioglycollate-elicited, and lymphokine-treated macrophages
plated on coverslips coated with BSA-anti-BSA complexes lost the ability to bind and
ingest E(IgG) (data not shown) .
These results indicate that C3b receptors of macrophages that are capable of
phagocytizing complement-coated erythrocytes disappear from the nonadherent sur-
face of macrophages plated on complement-coated immune complexes, whereas C3b
receptors of macrophages that are incapable of phagocytizing complement-coated E
cannot be modulated by complement-containing complexes . It has been suggested
that receptor disappearance is a consequence of receptor sequestration on immobilized
ligands (9, 10) . If that is the mechanism here, then these findings suggest that the
lymphokine acts by freeing anchored macrophage C3b receptors so that they can
move randomly within the plane of the macrophage plasma membrane and become
trapped on immobilized C3b ligands .
Effect of Lymphokine Preincubation on the Modulation ofMacrophage C36 Receptors.
￿
In the
above experiments, the complement receptor function of lymphokine-treated macro-
phages was assayed in the presence of lymphokine . We reasoned that if lymphokine
treatment freed previously anchored C3b receptors so that they could move within
the plasma membrane and become sequestered on complement-containing, immobi-
lized immune complexes, then the continued presence of lymphokine was probably
unnecessary, for once receptors were bound to complexes, they probably could not
migrate back to the nonadherent macrophage surface . The following experiments
were designed to examine the necessity for continuous lymphokine treatment . At the
same time, we determined the rate at which complement receptor activity was
modulated by the lymphokine .
When macrophages were incubated with lymphokine and E(IgM)C at 37°C in the
preceding experiments, four separate events were occurring simultaneously . The
lymphokine was exerting its effect on macrophage complement receptors, complement
receptors may have been moving within the plane of the macrophage plasma
membrane, E(IgM)C were settling onto macrophage monolayers, and macrophage
complement receptors were interacting with E(IgM)C . To determine the rate of
complement receptor modulation independently of E(IgM)C settling and binding,
we used the following protocol . Macrophages plated on BSA-anti-BSA-C complexes
Coverslip treatment Resident Thioglycollate-elicited Lymphokine-treated
PI AI PI AI PI AI
None 0 538 ± 18 331 ± 85 667 ± 21 113 ± 13 581 t 14
PLL-BSA 0 603 ± 54 398 ± 134 779 ± 96 122 ± 6 562 ± 39
PLL-BSA-anti-BSA 0 590 ± 37 337 ± 97 680 t 89 114 ± 10 596 ± 7
PLL-BSA-anti-BSA-C 0 638 ± 32 2 ± 1 13 ± 2 0 21 1 4FRANK M. GRIFFIN, JR. AND PEGGY J. MULLINAX
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were incubated with lymphokine at 37°C for various periods of time. Cultures were
washed twice with ice-cold medium and E(IgM)C in ice-cold medium were added.
Cultures were incubated either at 4° C for 1 h or at 4 °C for the first 15 min and then
at 37 °C for the final 45 min. Because the lymphokine cannot act (8) and complement
receptor activity cannot be modulated at 4°C (data not shown), both the time during
which the lymphokine could act and the time during which complement receptor
modulation could occur were limited to the initial 37° C incubation. E(IgM)C binding
could then be assessed at 4 °C, independently of these events. The subsequent 45-min,
37 °C incubation was intended to allow time for recovery of macrophage complement
receptors from the effects of lymphokine treatment.
The results presented in Fig. I were obtained by incubating macrophages with
E(IgM)C first at 4°C for 15 min and then at 37 °C for 45 min ; identical kinetics were
obtained when macrophages were incubated with E(IgM)C at 4 °C for 1 h. Loss of
complement receptor activity from the nonadherent macrophage surface was apparent
after <2 min of lymphokine treatment, and the maximal lymphokine effect was
achieved by 5 min. Thus, the lymphokine modulates macrophage complement
receptor function very rapidly. Moreover, because complement receptor activity did
not return to the nonadherent macrophage surface during the 45-min, 37°C incuba-
tion after lymphokine removal, the continued presence of the lymphokine is not
necessary to maintain complement receptor modulation. These findings are consistent
with the receptors' being sequestered on immobilized immune complexes.
Recovery of C3b Receptor Activity after Modulation by the Lymphokine.
￿
In the following
experiments, we explored further the recovery of macrophage complement receptors
from the effects of lymphokine treatment. Macrophages plated on BSA-anti-BSA-C
complexes were treated with lymphokine for 15 min at 37 °C, washed, covered with
either medium or cyclohexamide, and replaced at 37 °C. At various times thereafter,
macrophage complement receptor function was assessed (Fig. 2) . Lymphokine-treated
macrophages recovered complement receptor binding activity completely after a 4-h
incubation in medium. Recovery of receptor activity required macrophage protein
synthesis, for it did not occur in the presence of cyclohexamide. When cyclohexamide
was removed, macrophages regained receptor activity at the same rate as those not
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Effect of lymphokine preincubation on the modulation of macrophage C3b receptors.
Macrophages plated on BSA-anti-BSA-C complexes were treated with lymphokine for the periods
of time indicated on the abscissa, after which they were incubated with E(IgM)C at 4°C for 15 min
and then at 37°C for 45 min.296
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Recovery of C3b receptor activity after modulation by the lymphokine. Macrophages
plated on BSA-anti-BSA-C complexes were treated with lymphokine for 15 min at 37°C, then
incubated in either medium alone (C]) or in medium containing 5 !lg/ml of cyclohexamide (O) .
After a 4-h incubation with the drug, cyclohexamide-treated macrophages were washed and covered
with medium (arrow) . At the times indicated on the abscissa, the cells' ability to bind E(IgM)C was
determined.
treated with the drug, indicating that cyclohexamide treatment was not cytotoxic.
These results suggest that the return of complement receptor activity to the nonad-
herent surface of lymphokine-treated macrophages was dependent upon the synthesis
of new complement receptors and their insertion into the macrophage plasma
membrane.
Effect of Continuous Lymphokine Treatment on the Recovery of Macrophage C3b Receptor
Activity. Macrophages plated on BSA-anti-BSA-C complexes were treated with
lymphokine. Some cultures were washed after 15 min and covered with fresh medium;
others were left in lymphokine-containing medium for up to 24 h. As shown in Fig. 3,
all lymphokine-treated macrophages lost complement receptor activity. Those treated
for only 15 min recovered activity within 4 h of removal of the lymphokine. However,
the continuous presence of lymphokine completely inhibited the reappearance of
complement receptor activity on the nonadherent macrophage surface. Also shown in
Fig. 3, thioglycollate-elicited macrophages plated on BSA-anti-BSA-C-coated cover-
slips and incubated in medium similarly failed to recover complement receptor
function. These results suggest that in macrophages whose complement receptors are
unable to migrate within the plasma membrane, newly synthesized receptors inserted
into the nonadherent macrophage surface remain there and receptor activity is
recovered within a few hours. In contrast, in macrophages whose complement
receptors are able to move within the plasma membrane, newly synthesized receptors
inserted into the nonadherent macrophage surface quickly migrate to the adherent
cell surface and are trapped there, preventing recovery of receptor activity on the
nonadherent macrophage surface.
Release of Bound Complement Receptorsfrom Immobilized Immune Complexes.
￿
To prove
that migration to and sequestration on immobilized ligands was the mechanism by
which receptors disappeared from the nonadherent surface of macrophages plated on
immune complexes, we needed to demonstrate that complement receptors could beFRANK M. GRIFFIN, JR. AND PEGGY J. MULLINAX
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Effect of continuous lymphokine treatment on the recovery of macrophage C3b receptor
activity. Macrophages were plated on BSA-anti-BSA-C complexes. Some macrophages (O and ")
were treated with lymphokine; others (A) were not. Some macrophages (") were incubated with
lymphokine for the periods of time indicated on the abscissa. Others (O) remained in lymphokine
for only 15 min, after which they were incubated in medium alone for the periods of time indicated
on the abscissa. Thioglycollate-elicited macrophages (O) were plated on BSA-anti-BSA-C complexes
and incubated in medium alone for the periods oftime indicated on the abscissa. At the conclusion
of the incubations, the ability of macrophages to bind E(IgM)C wasdetermined.
released from the immobilized ligands and could redistribute over the macrophage
surface. Preliminary experiments indicated that pretreatment of BSA-anti-BSA-C-
coated coverslips with heat-inactivated (56°C for 30 min) mouse serum, but not with
fresh mouse serum, markedly altered the complexes. Macrophages plated on these
coverslips and treated with lymphokine retained their ability to bind E(IgM)C (data
not shown), suggesting that C3b inactivator (C3b INA) in the serum cleaved C3b
ligands from immobilized complexes. We reasoned that C3b INA in heat-inactivated
serum might also cleave complement receptor-bound C3b from immobilized immune
complexes, thereby releasing the bound complement receptors.
Macrophages plated on BSA-anti-BSA-C complexes were treated with lymphokine
for 15 min, lymphokine was removed, and cultures were incubated for 45 min at
37°C with either fresh medium alone or with medium containing 30% heat-inactivated
mouse serum . Lymphokine-treated macrophages incubated in medium alone were
unable to bind E(IgM)C (Fig. 4, bar B), whereas those in cultures subjected to
treatment with heat-inactivated mouse serum (Fig. 4, bar C) were as capable of
binding E(IgM)C as were macrophages that had been plated on BSA-anti-BSA-C-
coated coverslips and not subjected to lymphokine treatment (Fig. 4, bar A) . Similarly,
thioglycollate-elicited macrophages, which lost virtually all complement receptor
activity when plated on BSA-anti-BSA-C-coated coverslips (Table I), regained recep-
tor activity when treated with heat-inactivated mouse serum (data not shown).
It was possible that the rapid recovery of complement receptor activity by macro-
phages treated with heat-inactivated mouse serum was a result of the serum's
enhancing the cells' ability either to synthesize new complement receptors or to insert
complement receptors into their plasma membranes. To test these possibilities, we
performed experiments similar to those above, but using either fresh mouse serum,
which contains both C3b INA and C3b-generating capability and which therefore
would generate and deposit new C3b molecules on BSA-anti-BSA complexes at the
same time that it destroyed the previously bound C3b molecules, or heat-inactivated298
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Release of bound complement receptors from immobilized immune complexes. Macro-
phages plated on BSA-anti-BSA-C complexes were either incubated in medium alone (bar A) or
treated with lymphokine for 15 min at 37°C (bars B-E) . They were then washed and treated with
either heat-inactivated mouse serum (bar C), fresh mouse serum (bar D), or heat-inactivated FBS
(bar E) for 45 min at 37°C. Some macrophages were incubated at 37°C sequentially with 5 Ag/ml
of cyclohexamide for 1 h, with lymphokine for 15 min, and with either medium alone (bar F) or
heat-inactivated mouse serum (bar G) for 45 min, cyclohexamide being included in the latter two
incubations as well. At the conclusion of the incubations, macrophages were washed and covered
with fresh medium and their ability to bind E(IgM)C was determined.
FBS, serum that contains "nutritional factors" similar to those of mouse serum but
contains C3b INA that we speculated might be incapable of recognizing mouse C3b.2
Both of these sera should provide components and activities similar to those of heat-
inactivated mouse serum, but neither should cause a net loss of C3b ligands from
immobilized immune complexes. Treatment with these sera did not restore comple-
ment receptor activity to the nonadherent macrophage surface (Fig. 4, bars D and E) .
In other experiments, macrophages plated on BSA-anti-BSA-C complexes were
treated at 37°C sequentially with cyclohexamide for 1 h, with lymphokine for 15
min, and with either medium alone or 30% heat-inactivated mouse serum for 45 min,
cyclohexamide being included in the latter two incubations as well. Macrophages
treated with cyclohexamide and then with lymphokine did not bind E(IgM)C (Fig.
4, bar F) ; in contrast, macrophages treated with cyclohexamide and lymphokine and
then with heat-inactivated mouse serum were able to bind E(IgM)C normally (Fig.
4, bar G). Thus, the lymphokine modulates, and heat-inactivated mouse serum
restores, complement receptor activity by mechanisms that are independent of mac-
rophage protein synthesis.
These results exclude the possibility that the rapid recovery ofcomplement receptor
function by macrophages treated with heat-inactivated mouse serum was the result of
either enhanced synthesis of complement receptors or of an enhanced rate of insertion
of complement receptors into the macrophage plasma membrane. They strongly
suggest that C3b INA and proteases in heat-inactivated mouse serum cleaved immune
complex-bound C3b, thereby releasing C3b receptors from the immobilized ligands
and permitting them to return to their former positions over the entire macrophage
surface. Thus, the results provide strong support for the hypothesis that the mechanism
by which complement receptors disappear from the nonadherent surface of macro-
' We are unaware of any information regarding the species specificity of bovine C3b inactivater.FRANK M. GRIFFIN, JR. AND PEGGY J. MULIANAX
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phages plated on immune complexes and treated with lymphokine is by migrating to
and becoming sequestered on immobilized C3b ligands.
Further Definition of the Mechanism of Action of the Lymphokine.
￿
Previous work from
this laboratory (13) has shown that treatment of macrophages with pharmacologically
achievable concentrations of hydrocortisone completely abolishes the cells' ability to
respond to the lymphokine and phagocytize via their complement receptors. To
determine whether hydrocortisone treatment also inhibits the lymphokine's effect on
complement receptor mobility, we treated macrophages plated on BSA-anti-BSA-C
complexes with 10-a M hydrocortisone for 1 h at 37 °C, washed the cells with medium,
treated them with lymphokine for 15 min at 37 °C, and determined their interaction
with E(IgM)C. These macrophages bound E(IgM)C normally (Fig. 5, bar C),
indicatingthat hydrocortisone abrogates the effect of the lymphokine on macrophage
complement receptor mobility and suggesting that the lymphokine enables comple-
ment receptors to move within the macrophage plasma membrane by the same
mechanism as it enables them to promote phagocytosis.
To explore further the mechanism by which the lymphokine acts on macrophage
complement receptors, we treated macrophages plated on BSA-anti-BSA-C complexes
with either 10-s M colchicine or 10-s M vinblastine for 1 h at 37°C, then treated
them with lymphokine for 15 min at 37°C, maintaining the drug in this incubation
mixture as well. Macrophages were washed and their interaction with E(IgM)C was
assessed. These macrophages avidly bound E(IgM)C (Fig. 5, bars D and E) . That the
drugs achieved their effect by depolymerizing the macrophages' microtubules was
indicated by the ineffectiveness of lumicolchicine (Fig. 5, bar F), a photoisomer that
retains many of the effects of colchicine but does not bind tubulin or depolymerize
microtubules (14), and by the ability of taxol, a microtubule-stabilizing agent (15-
17), to prevent the effect of colchicine (Fig. 5, bar G) . Colchicine pretreatment did
not prevent the disappearance ofcomplement receptor activity from the nonadherent
surface of thioglycollate-elicited macrophages when they were plated on BSA-anti-
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FIG. 5. Effects of hydrocortisone and of microtubule depolymerization on the effect of the
lymphokine on macrophage complement receptor mobility. Macrophages plated on BSA-anti-BSA-
C complexes were either incubated in medium alone (bar A) or treated with lymphokine for 15 min
at 37°C (bars B-G) . Some macrophages were pretreated either with 10-e M hydrocortisone for l h
at 37° C (bar C), or with 10-e M colchicine (bar D), 10-s M vinblastine (bar E), or 10-s M
lumicolchicine (bar F) for 2 h at 37°C before lymphokine treatment. Some macrophages were
pretreated with 5 X 10-s M taxol for 1 h at 37 °C and then with 10-s M colchicine for 2 h at 37°C
before lymphokine treatment (bar G) . At the conclusion of the incubations, macrophages were
washed and covered with fresh medium and their ability to bind E(IgM)C was determined.300
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BSA-C complexes (data not shown), indicating that intact microtubule function is
not required for complement receptor mobility per se. The inhibition of lymphokine-
induced complement receptor modulation by colchicine and vinblastine indicates,
therefore, that intact microtubule function is necessary for macrophages to respond to
the lymphokine.
Discussion
We considered four mechanisms by which plating macrophages on immobilized
immune complexes might cause the disappearance of receptor activity from the
nonadherent macrophage surface:
(a) Immune complexes might detach from the glass surface and bind to receptors
over the entire macrophage surface. This seems unlikely to account for our findings,
however, because soluble immune complexes, which can very efficiently block mac-
rophage Fc receptors, appear to be unable to block macrophage C3b receptors, even
when they contain complement (13, 18) . In addition, Rabinovitch et al. (19) and
Michl et al. (9) have demonstrated that during several hours of incubation at 37°C
virtually no immune complexes detach from the coverslips and bind to the nonad-
herent macrophage surface.
(b) Engagement by immobilized ligands of receptors on the adherent surface of the
mononuclear phagocyte triggers a number of metabolic events that result in release
into the culture medium of neutral proteases (20), lysosomal enzymes (20), toxic
products of oxygen metabolism (21), and probably prostaglandins (22), any of which
might damage receptors on the nonadherent macrophage surface. Such a mechanism
would not explain the selectivity of receptor inactivation seen, for example, in
macrophages plated on antigen-antibody complexes; whereas their Fc receptor activity
was virtually nil, their complement receptor activity was normal (9) . Moreover,
Ragsdale and Arend (23) have presented strong evidence against the participation of
either neutral proteases, lysosomal hydrolases, H202, superoxide anion, or prostaglan-
dins in receptor inactivation.
(c) Engagement of immobilized ligands by receptors on the adherent macrophage
surface might initiate intracellular metabolic events that cause changes in either the
number or the function of identical receptors on the nonadherent macrophage surface.
Ragsdale and Arend (23) have, in fact, presented evidence that supports a cAMP-
mediated reaction leading to the abolition of Fc receptor activity from the nonadher-
ent surface of human monocytes plated on immune complexes. These investigators
proposed that engagement of Fc receptors on the adherent monocyte surface led either
to phosphorylation of the remaining Fc receptors or to activation of phospholipases
that inactivated Fc receptors located on the nonadherent surface of the cells. This
formulation does not readily explain the selectivity ofreceptor inactivation. Moreover,
Michl et al. (10) have found that mouse peritoneal macrophages plated on antigen-
antibody complexes bind <25% as much monoclonal anti-Fc receptor antibody as
their counterparts plated on coverslips without complexes. Thus, Fc receptors on the
nonadherent macrophage surface are more than functionally altered; they are either
severely modified antigenically or absent from that macrophage surface.
(d) All, or nearly all, receptors might migrate to the adherent surface of macro-
phages plated on immune complexes, leaving the nonadherent surface both function-
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within the macrophage plasma membrane is an unlikely explanation for these findings
because pharmacologic agents that inhibit capping of certain surface antigens by
some cells do not prevent the disappearance of receptor activity from the macrophage
surface (23). Capping is the surface aggregation of plasma membrane molecules that
is induced by the binding of a multivalent ligand and that is under the control of
certain intracellular structures, e.g., actin filaments (24-31) . Our finding that com-
plement receptor activity reappeared on the nonadherent macrophage surface
promptly after treatment of immune complex-bound, lymphokine-treated macro-
phages with C3b INA (Fig. 4) strongly suggests that all C3b receptors had been
sequestered on immobilized ligands and that they were freed to redistribute over the
macrophage surface once the C3b ligand was destroyed. We therefore believe that
receptor movement within the macrophage plasma membrane does account for the
experimental findings, but we think that the movement involved is not capping but
rather the random mobility of receptor molecules in the plasma membrane's fluid
bilayer (25, 32, 33) . This mechanism most reasonably deals with all experimental
findings. It explains the selectivity of receptor inactivation. It also explains how Fc
receptor activity of all mononuclear phagocytes (23; and S. C. Silverstein, personal
communication) and complement receptor activity of thioglycollate-elicited macro-
phages (Fig. 3), once modulated, fail to reappear on the nonadherent cell surface,
whereas complement receptor activity returns to the nonadherent surface of lympho-
kine-treated macrophages within 4 h of lymphokine removal. Fc receptors are
intrinsically able to move within the plane of the macrophage plasma membrane
(10). Thus, in macrophages plated on immune complexes, whenever a newly synthe-
sized Fc receptor is inserted into the plasma membrane, it wanders randomly within
the membrane, finds its way to the adherent macrophage surface, and is bound there.
Fc receptor activity cannot return to the nonadherent macrophage surface until
immobilized IgG ligands have been saturated with Fc receptors. Similar arguments
probably explain the failure of complement receptor activity to reappear on the
nonadherent surface of thioglycollate-elicited macrophages plated on complement-
containing, immobilized immune complexes. Complement receptor activity does not
disappear from the nonadherent surface of resident peritoneal macrophages plated on
antigen-antibody-complement complexes, presumablybecause, like the C3b receptors
of human neutrophils (34), these receptors are normally fixed within the macrophage
plasma membrane. Treatment of resident macrophages with the lymphokine that
augments their complement receptor function releases complement receptors from
their plasma membrane anchors and permits them to move randomly within the
membrane. As they encounter immobilized C3b ligands on the immune complex
substrate, they are trapped on the adherent macrophage surface. As newly synthesized
complement receptors are inserted into the macrophage plasma membrane, they
similarly wander to the adherent cell surface and become trapped on the immobilized
complexes. If this explanation is correct, complement receptor activity should not
reappear on the nonadherent surface of immune complex-bound macrophages so long
as they are in the presence of lymphokine; however, receptor activity should progres-
sively reappear after lymphokine is removed . As shown in Fig. 3, this is precisely the
case.
Previous studies have indicated that whereas macrophages were able to phagocytize
E(IgM)C in the presence of the lymphokine (8), macrophages preincubated with the302
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lymphokine for up to several hours were unable to ingest E(IgM)C after lymphokine
removal (7) . In light of the results obtained here with regard to modulation of
complement receptor topography by the lymphokine, these previous results suggest
that the normally anchored C3b receptors are freed by the lymphokine to move
randomly in the plane of the plasma membrane. If engaged by C3b ligands while in
the presence of the lymphokine, the receptors become functionally linked to the cell's
phagocytic machinery, leading to phagocytosis of particles coated with C3b . If not
engaged by C3b ligands while the lymphokine is present, they return promptly to
their anchored state when the lymphokine is removed .
Many plasma membrane receptors are mobile in either their free or their ligand-
bound states (35-40) ; and certain receptors, when engaged by their ligands, must
move laterally within the plasma membrane for ligand-receptor binding to be
translated into altered cell behavior or metabolism (35, 36, 38) . In some cases, lateral
mobility of receptors serves to link them with intramembrane second messenger
molecules (35-38) . In others, aggregation of ligand-bound receptors with each other
is required to generate an intracellular response (26, 28-30, 37), and receptor
aggregation may result in the physical linking of receptors with intracellular structures .
For example, /3z-rnicroglobulin, aminopeptidase, Na+,K+-ATPase, B lymphocyte
surface immunoglobulin, and concanavalin A receptors are normally freely mobile
within the plasma membrane but become fixed to actomyosin when bound by their
specific antibodies or lectin (25, 26, 28-30) .
Results ofseveral studies (9, 13, 19, 23, 40, 41, and this paper) demonstrate a precise
correlation between the ability of receptors to redistribute on the macrophage surface
and their ability to promote phagocytosis (Table II), suggesting that receptor mobility
may be an essential component of the phagocytic signal . We propose the following
model for the initiation and transmission of that signal . Receptors that are wandering
TABLE II
Correlation between the Mobility ofFc and C3b Receptors on the Mononuclear Phagocyte's Surface and the
Receptors' Ability to Promote Phagocytosis
* Colchicine's inhibition of the lymphokine's effect on macrophage complement receptor mobility is shown
in Fig . 5 . Data for the effects ofcolchicine on Fc receptor mobility and on Fc receptor- and C3b receptor-
mediated phagocytosis are not shown .
Mononuclear phagocyte
Fc Receptor
Mobil- Phago-
ity cytosis
C3b
Mobil-
ity
Receptor
Phago-
cytosis
References
Human monocyte + + - - 23,40
Resident mouse peritoneal macro- + + - - 9, 19, 41, this paper
phage
Thioglycollate-elicited mouse peri- + + + + 9, this paper
toneal macrophage
Lymphokine-treated mouse perito- + + + + This paper
neal macrophage
Hydrocortisone-pretreated, lympho- + + - - 13, this paper
kine-treated mouse peritoneal
macrophage
Colchicine-pretreated, lymphokine- + + - - This paper
treated mouse peritoneal macro-
phage*randomly
within the macrophage plasma membrane become engaged by appropriate
particle-bound
ligands
.
It may be that ligand engagement of the mobile receptors
initiates
the phagocytic signal by directing the individual receptors to an intramem-
brane
second messenger molecule
.
Alternatively, the ligand-bound receptors may first
aggregate
on the cell surface and then become functionally and perhaps physically
linked
with the intracellular phagocytic machinery, and actin and its regulatory
proteins
(42, 43)
.
Changes in the physical state of actin then provide the motive force
for
ingestion of the ligand-coated particle
.
Summary
We
have previously reported that treatment with a unique lymphokine enables
resident
mouse peritoneal macrophages to phagocytize via theircomplement receptors
and
we have presented evidence that the lymphokine acts by enabling complement
receptor
engagement by C3b ligands to generate a phagocytic signal, thereby linking
the
cell surface binding event with the intracellular phagocytic machinery
.
In the
present
experiments, we used immobilizedimmune complexes to study the topography
of
C3b receptors of resident mouse peritoneal macrophages treated with the lympho-
kine .
Our results indicate that lymphokine treatment enables the macrophages' C3b
receptors
to migrate within the plane of the cells' plasma membrane and that
manipulations
of macrophages that abrogate one response to the lymphokine, com-
plement
receptor mobility, also abrogate the other response, complement receptor-
mediated
phagocytosis
.
These findings strongly suggest that lateral mobility of a
ligand-bound
receptor within the macrophage plasma membrane is an essential
component
of the phagocytic signal
.
Moreover, our results indicate that the difference
in
complement receptor function among various populations of macrophages is not
due
to the expression of different types of complement receptors by the different
macrophage
populations but rather to a difference in the relationship of the C3b
receptor
with other plasma membrane or intracellular components
.
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